Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
Authors found that in 23.6% of a random sample of 2,809 admissions, there were at least one adverse event. 316 of the 978 adverse events were classified as having a significant or higher severity level, and 222 were deemed to be preventable. In 6.8% of all admissions, an adverse event that could have been avoided happened, and in 1% of those cases, the incident had a serious or higher severity rating. Seven people passed away, one of which was thought to be avoidable. The most frequent adverse events (representing 39.0% of all occurrences) were adverse medication events, which were followed by surgical or other procedural events (30.4%), patient-care events (15.0%), and infections related to medical care (11.9%).
All Specialties January 18th 2023
Annals of Internal Medicine
This 70-study meta analysis concludes that the evidence is moderate to high that bisphosphonates and denosumab reduce the risk for hip, vertebral, and other fractures. The evidence is moderate to high that abaloparatide and teriparatide reduce clinical fractures and radiographic vertebral fractures, and low to moderate that SERMs reduce radiographic vertebral fractures, but not clinical fractures.
Family Medicine/General Practice January 11th 2023
Boston’s Children’s Hospital
Innovative and creative Risky Business events emphasize risk management, patient safety, and safety awareness. To enable all of their colleagues to work in a safer environment, they continuously “raise the bar” by exchanging safety ideas and experiences across industries. The integration of experiences from speakers representing a wide range of non-healthcare businesses into a coherent narrative and actionable results is a crucial component of Risky Business. In this two-hour video webinar taking place on Thursday, January 12 from 10:00 AM to noon , the panelists will talk about a wide range of topics, including systemic problems, workforce implications, community needs, and what industry experts are doing to address the situation. To address challenges of capacity and resource strain, they will examine cutting-edge digital technology and government and healthcare system collaboration.
Family Medicine/General Practice January 10th 2023
OBR Oncology
Mikkael A. Sekeres, MD, currently Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center at the University of Miami, worked on the decision to remove Avastin’s indication for the treatment of HER2-negative metastatic breast cancer in 2008. As a result of the hearing, Dr. Sekeres poses the following question in his most recent book, Drugs and the FDA: Safety, Efficacy, and the Public’s Trust: “Had the FDA made a mistake in initially approving the drug?” Dr. Sekeres discussed with OBR the rise of accelerated approvals, progression-free survival as an endpoint, and the consequences of the Avastin hearing.
Hematology/Oncology November 14th 2022
Medical records of more than half a million individuals in the EU, UK, and US were evaluated. Apixaban was the most frequently prescribed direct oral anticoagulant (DOAC) for AFib. It was also associated with a lower incidence of GI bleed vs. the other DOACs.
Cardiology November 9th 2022
JAMA Network
The 100-μg dose of the ERBB2 ICD plasmid-based vaccine was associated with the generation of ERBB2-specific type 1 T cells in the majority of patients with ERBB2-expressing breast cancer in this phase 1 nonrandomized clinical trial, and it is currently being assessed in randomized phase 2 trials.
Oncology, Medical November 7th 2022